Qinghai Spring Medicinal Resources Technology
Market Cap
CN¥3.5b
Last Updated
2021/04/17 09:03 UTC
Data Sources
Company Financials
Executive Summary
Qinghai Spring Medicinal Resources Technology Co., Ltd. More Details
Risk Analysis
Snowflake Analysis
Flawless balance sheet and overvalued.
Share Price & News
How has Qinghai Spring Medicinal Resources Technology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 600381 is more volatile than 90% of CN stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 600381's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.
Market Performance
7 Day Return
2.6%
600381
-2.8%
CN Pharmaceuticals
-0.8%
CN Market
1 Year Return
26.3%
600381
10.4%
CN Pharmaceuticals
25.0%
CN Market
Return vs Industry: 600381 exceeded the CN Pharmaceuticals industry which returned 10.4% over the past year.
Return vs Market: 600381 exceeded the CN Market which returned 25% over the past year.
Shareholder returns
| 600381 | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.6% | -2.8% | -0.8% |
| 30 Day | -4.6% | 1.0% | -0.08% |
| 90 Day | -11.6% | -5.1% | -5.3% |
| 1 Year | 26.3%26.3% | 11.5%10.4% | 27.0%25.0% |
| 3 Year | -40.3%-40.3% | 25.2%20.8% | 29.1%22.8% |
| 5 Year | n/a | 46.5%38.7% | 30.5%21.7% |
Long-Term Price Volatility Vs. Market
How volatile is Qinghai Spring Medicinal Resources Technology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Qinghai Spring Medicinal Resources Technology undervalued compared to its fair value and its price relative to the market?
1.54x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 600381's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 600381's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 600381 is unprofitable, so we can't compare its PE Ratio to the CN Pharmaceuticals industry average.
PE vs Market: 600381 is unprofitable, so we can't compare its PE Ratio to the CN market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 600381's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 600381 is good value based on its PB Ratio (1.5x) compared to the CN Pharmaceuticals industry average (2.7x).
Future Growth
How is Qinghai Spring Medicinal Resources Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
24.3%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Qinghai Spring Medicinal Resources Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Qinghai Spring Medicinal Resources Technology performed over the past 5 years?
-45.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 600381 is currently unprofitable.
Growing Profit Margin: 600381 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 600381 is unprofitable, and losses have increased over the past 5 years at a rate of 45.6% per year.
Accelerating Growth: Unable to compare 600381's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 600381 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.3%).
Return on Equity
High ROE: 600381 has a negative Return on Equity (-3.02%), as it is currently unprofitable.
Financial Health
How is Qinghai Spring Medicinal Resources Technology's financial position?
Financial Position Analysis
Short Term Liabilities: 600381's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥10.5M).
Long Term Liabilities: 600381's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥3.7M).
Debt to Equity History and Analysis
Debt Level: 600381 is debt free.
Reducing Debt: 600381 has no debt compared to 5 years ago when its debt to equity ratio was 0.6%.
Debt Coverage: 600381 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 600381 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Qinghai Spring Medicinal Resources Technology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 600381's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 600381's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 600381's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 600381's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 600381's dividend in 3 years as they are not forecast to pay a notable one for the CN market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Qinghai Spring Medicinal Resources Technology has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Qinghai Spring Medicinal Resources Technology Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Qinghai Spring Medicinal Resources Technology Co., Ltd.
- Ticker: 600381
- Exchange: SHSE
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥3.462b
- Shares outstanding: 587.06m
- Website: https://www.verygrass.com
Number of Employees
Location
- Qinghai Spring Medicinal Resources Technology Co., Ltd.
- Ningjing Business Center
- 16th Floor
- Xining
- Qinghai Province
- 810007
- China
Listings
Biography
Qinghai Spring Medicinal Resources Technology Co., Ltd. explores and develops natural medicinal resources on the Qinghai-Tibet Plateau. It provides polar and Herborist grass 5X cordyceps sinensis series of...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/17 09:03 |
| End of Day Share Price | 2021/04/16 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.